Please assess the completion status of the following clinical trial:

Trial Title: GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatoid arthritis as defined by the 1987 ACR classification~* Severe active seropositive disease~* Inadequate response or intolerance to other DMARDs and anti-TNFs~* Treatment with Methotrexate~Exclusion Criteria:~* Patients with systemic manifestations of rheumatoid arthritis~* Female patients nursing~* Women of childbearing potential unless using birth control~* Active infection~* Known immunodeficiency syndrome~* Positive Hepatitis B surface antigen or antibodies to Hepatitis C~* History of cancer~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP2013 (Type: EXPERIMENTAL): None
- MabThera (Type: ACTIVE_COMPARATOR): None
- Rituxan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).